オプトレギュレーションされたmRNA配送は,腫瘍標的治療のためのプレオトロプ免疫シグナリングを制御する
Pengwen Chen1, Guanghao Hu1, Yuki Nakashima1
1Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Angewandte Chemie (International ed. in English)
|September 2, 2025
まとめ
新しい光誘発伝染システム (LITS) は,メッセンジャーRNA (mRNA) 治療法を正確に制御することができます. このシステムは,腫瘍における標的型タンパク質発現を可能にし,より安全な治療のために毒性を最小限に抑えながら,抗腫瘍活動を強化します.
科学分野:
- バイオテクノロジー
- 治療薬
- 分子生物学
背景:
- タンパク質発現の空間時間的制御は,特に腫瘍を標的とする治療において,mRNA療法において極めて重要です.
- 現在の方法は,mRNA治療の正確な投与と局所的活性化を達成する上で課題に直面しています.
研究 の 目的:
- 光誘発感染システム (LITS) を導入し,mRNAトランスレーションを空間時間的に制御する.
- 標的組織における局所的なタンパク質発現と治療効果の調節のためのLITSの能力を実証する.
主な方法:
- システム的なmRNA配送のために光感受性ポリマーを使用してLITSを開発しました.
- 放射線を受けた組織における光誘発内体脱出による活性化されたmRNA翻訳.
- LITSの有効性を評価するためのモデル治療薬としてインタールイキン-2 (IL-2) を利用した.
主要な成果:
- LITSは,放射線を受けた腫瘍で局所的なタンパク質発現を可能にし,炎症誘発性サイトカインレベルを誘発した.
- 放射線を受けていない健康な組織は,全身の毒性を減少させる,許容性IL-2濃度を示した.
- LITSは乳がんモデルでIL-2の有効性を同調し,免疫細胞死と肺転移を根絶しました.
結論:
- LITSは,オンデマンドの標的型mRNA治療のためのプログラム可能なプラットフォームを提供します.
- このシステムはタンパク質発現の 精密な空間制御を提供し 治療効果を高めます
- LITSはIL-2の効果を調節することで,安全で効果的ながん治療の可能性を示しています.
関連する概念動画
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Experimental RNAi
6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K


